RANKL Antibody (12A668): sc-52950

RANKL Antibody (12A668) is a mouse monoclonal IgG1 antibody raised against amino acids 1-317 of RANKL of mouse origin, effectively detecting RANKL proteins from mouse, rat, and human origins by western blotting (WB), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). RANKL, also known as Receptor Activator of Nuclear Factor Kappa-B Ligand, TNFSF11, TRANCE, OPGL, or ODF, is a type II transmembrane protein that plays a pivotal role in bone remodeling and immune system regulation. By binding to its receptor RANK on osteoclasts and dendritic cells, RANKL activates critical signaling pathways such as NF-κB and JNK, leading to osteoclast differentiation and activation. This interaction is essential for normal bone resorption and remodeling processes; however, dysregulation of RANKL expression is associated with pathological conditions like osteoporosis, rheumatoid arthritis, and bone metastasis. Understanding the function of RANKL is important for developing therapeutic interventions targeting bone diseases and immune disorders. RANKL monoclonal antibody (12A668) helps researchers gain valuable insights into the mechanisms of bone metabolism and immune responses mediated by RANKL. RANKL (12A668) antibody serves as a vital tool for advancing studies in osteoclast biology and related pathological conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RANKL Antibody (12A668) References:

1. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene.  |  Kim, N., et al. 2000. Proc Natl Acad Sci U S A. 97: 10905-10. PMID: 10984520
2. RANK ligand and osteoprotegerin in myeloma bone disease.  |  Sezer, O., et al. 2003. Blood. 101: 2094-8. PMID: 12424190
3. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells.  |  Loser, K., et al. 2006. Nat Med. 12: 1372-9. PMID: 17143276
4. RANKL biology: bone metabolism, the immune system, and beyond.  |  Ono, T., et al. 2020. Inflamm Regen. 40: 2. PMID: 32047573
5. Osteoclast differentiation by RANKL and OPG signaling pathways.  |  Udagawa, N., et al. 2021. J Bone Miner Metab. 39: 19-26. PMID: 33079279
6. Discovery of the RANKL/RANK/OPG system.  |  Yasuda, H. 2021. J Bone Miner Metab. 39: 2-11. PMID: 33389131
7. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.  |  Wong, BR., et al. 1997. J Biol Chem. 272: 25190-4. PMID: 9312132
8. Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor kappaB (NFkappaB)-inducing kinase requirement for activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal kinase/stress-activated protein kinase.  |  Natoli, G., et al. 1997. J Biol Chem. 272: 26079-82. PMID: 9334169
9. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.  |  Anderson, DM., et al. 1997. Nature. 390: 175-9. PMID: 9367155
10. Activation of stress-activated protein kinase/c-Jun N-terminal kinase, but not NF-kappaB, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway.  |  Shi, CS. and Kehrl, JH. 1997. J Biol Chem. 272: 32102-7. PMID: 9405407
11. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase.  |  Darnay, BG., et al. 1998. J Biol Chem. 273: 20551-5. PMID: 9685412
12. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor.  |  Wong, BR., et al. 1998. J Biol Chem. 273: 28355-9. PMID: 9774460

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-RANKL Antibody (12A668) has 17 citations in a variety of scientific publications.

Primary antibodies like Anti-RANKL Antibody (12A668) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

RANKL Antibody (12A668) Specifications

Alternate Product Name: TNFSF11

Product Clone Name: 12A668

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids: 1-317

Epitope Target: RANKL

Epitope Species: mouse

Product Reactivity/Detection: RANKL

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, IHC(P)

Vialing Information: Each vial contains 50 µg IgG₁ in 0.5 ml of PBS with < 0.1% sodium azide, 0.1% gelatin and < 0.1% stabilizer protein

Research Citations: 17 citations in various scientific publications

Available Conjugates/Forms for RANKL Antibody (12A668): N/A